In this interview, Amir Reichman, BiondVax’s new CEO, discusses why he left GSK Vaccines after many years of senior leadership positions to lead BiondVax, a small biopharmaceutical company in Israel. He also discusses his short-term goals and long-term vision for the company.
BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and, ultimately, commercialising products for the prevention and treatment of infectious diseases and related illnesses. The company had been developing M‑001, a novel influenza vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future seasonal and pandemic influenza. In seven Phase I/II and Phase II clinical trials designed to test for immunogenicity, the company was able to demonstrate that M-001 was effective in stimulating an immune response to a broad range of influenza virus strains. In October 2020, BiondVax completed a Phase III clinical trial of M‑001 that failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space towards developing a pipeline of diversified products and platforms.